Designing Approaches to Multitarget Drugs

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Unknown venue

• Publication date

  2017-12-08

• Fields of study

  Medicine, Chemistry, Computer Science

• Identifiers
  DOI 10.1002/9783527674381.CH7
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Multitarget drug discovery for Alzheimer's disease: triazinones as BACE-1 and GSK-3β inhibitors.

  2015cited by this paper
• Fragment-Based Drug Discovery Targeting Inhibitor of Apoptosis Proteins: Discovery of a Non-Alanine Lead Series with Dual Activity Against cIAP1 and XIAP.

  2015cited by this paper
• Discovery of Multitarget-Directed Ligands against Alzheimer's Disease through Systematic Prediction of Chemical-Protein Interactions

  2015cited by this paper
• AlzPlatform: An Alzheimer’s Disease Domain-Specific Chemogenomics Knowledgebase for Polypharmacology and Target Identification Research

  2014cited by this paper
• Multi-objective molecular de novo design by adaptive fragment prioritization.

  2014cited by this paper
• Development of Dual Inhibitors against Alzheimer's Disease Using Fragment-Based QSAR and Molecular Docking

  2014cited by this paper
• De Novo Design of Multitarget Ligands with an Iterative Fragment-Growing Strategy

  2014cited by this paper
• Erratum to “Biodistribution and SPECT Imaging Study of 99mTc Labeling NGR Peptide in Nude Mice Bearing Human HepG2 Hepatoma”

  2014cited by this paper
• On the origins of drug polypharmacology

  2013cited by this paper
• The economics of polypharmacology: fixed dose combinations and drug cocktails.

  2013cited by this paper
• An Innovative Strategy for Dual Inhibitor Design and Its Application in Dual Inhibition of Human Thymidylate Synthase and Dihydrofolate Reductase Enzymes

  2013cited by this paper
• Molecular signatures of G-protein-coupled receptors

  2013cited by this paper
• A decade of change.

  2013cited by this paper
• mTOR kinase structure, mechanism and regulation by the rapamycin-binding domain

  2013cited by this paper
• Optimization of 5-hydroxytryptamines as dual function inhibitors targeting phospholipase A2 and leukotriene A4 hydrolase.

  2013cited by this paper
• Designed multiple ligands in metabolic disease research: from concept to platform.

  2013cited by this paper
• Predicting targeted polypharmacology for drug repositioning and multi- target drug discovery.

  2013cited by this paper
• Azepines and piperidines with dual norepinephrine dopamine uptake inhibition and antidepressant activity.

  2013cited by this paper
• Multitarget fragment‐based design of novel inhibitors for AChE and SSAO/VAP‐1 enzymes

  2013cited by this paper
• Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor

  2013cited by this paper
• 1-substituted (Dibenzo[b,d]thiophen-4-yl)-2-morpholino-4H-chromen-4-ones endowed with dual DNA-PK/PI3-K inhibitory activity.

  2013cited by this paper
• Systematic exploration of dual-acting modulators from a combined medicinal chemistry and biology perspective.

  2013cited by this paper
• Target identification and mechanism of action in chemical biology and drug discovery.

  2013cited by this paper
• Exploring the chemical space of multitarget ligands using aligned self-organizing maps.

  2013cited by this paper
• Targeting gain of function and resistance mutations in Abl and KIT by hybrid compound design.

  2013cited by this paper
• Multi-target inhibitors for proteins associated with Alzheimer: in silico discovery using fragment-based descriptors.

  2013cited by this paper
• A Pharmacological Organization of G Protein-coupled Receptors

  2012cited by this paper
• Potent, selective, and orally bioavailable inhibitors of the mammalian target of rapamycin kinase domain exhibiting single agent antiproliferative activity.

  2012cited by this paper
• Designed multiple ligands: basic research vs clinical outcomes.

  2012cited by this paper
• Dual inhibitors for aspartic proteases HIV-1 PR and renin: advancements in AIDS-hypertension-diabetes linkage via molecular dynamics, inhibition assays, and binding free energy calculations.

  2012cited by this paper
• Phenotype-based high-content chemical library screening identifies statins as inhibitors of in vivo lymphangiogenesis

  2012cited by this paper
• GPR119 as a fat sensor.

  2012cited by this paper
• Fragment-based lead discovery grows up

  2012cited by this paper
• Chemical genetic discovery of targets and anti-targets for cancer polypharmacology

  2012cited by this paper
• Vemurafenib: the first drug approved for BRAF-mutant cancer

  2012cited by this paper
• Activity landscape modeling of PPAR ligands with dual-activity difference maps.

  2012cited by this paper
• Automated design of ligands to polypharmacological profiles

  2012cited by this paper
• Identification and characterization of carprofen as a multitarget fatty acid amide hydrolase/cyclooxygenase inhibitor.

  2012cited by this paper
• Phenotypic screening, take two

  2012cited by this paper
• A series of case studies: practical methodology for identifying antinociceptive multi-target drugs.

  2012cited by this paper
• The Role of Chemogenomics in the Pharmaceutical Industry

  2012cited by this paper
• Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells.

  2012cited by this paper
• Modern phenotypic drug discovery is a viable, neoclassic pharma strategy.

  2012cited by this paper
• VS-5584, a Novel and Highly Selective PI3K/mTOR Kinase Inhibitor for the Treatment of Cancer

  2012cited by this paper
• Life beyond kinases: structure-based discovery of sorafenib as nanomolar antagonist of 5-HT receptors.

  2012cited by this paper
• An example of designed multiple ligands spanning protein classes: dual MCH-1R antagonists/DPPIV inhibitors.

  2012cited by this paper
• Regulation of monoamine transporters: Role of transporter phosphorylation.

  2011cited by this paper
• Selectivity of kinase inhibitor fragments.

  2011cited by this paper
• Recent advances in the search for D3- and D4-selective drugs: probes, models and candidates.

  2011cited by this paper
• Fragment library screening reveals remarkable similarities between the G protein-coupled receptor histamine H4 and the ion channel serotonin 5-HT3A

  2011cited by this paper
• Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer.

  2011cited by this paper
• Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.

  2011cited by this paper
• 1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: further insights into a class of triple re-uptake inhibitors.

  2011cited by this paper
• Discovery of benzimidazole derivatives as novel multi-target EGFR, VEGFR-2 and PDGFR kinase inhibitors.

  2011cited by this paper
• ChEMBL: a large-scale bioactivity database for drug discovery

  2011cited by this paper
• How were new medicines discovered?

  2011cited by this paper
• Exploration of acridine scaffold as a potentially interesting scaffold for discovering novel multi-target VEGFR-2 and Src kinase inhibitors.

  2011cited by this paper
• Synthesis of monomeric derivatives to probe memoquin's bivalent interactions.

  2011cited by this paper
• Fragment-based drug design and drug repositioning using multiple ligand simultaneous docking (MLSD): identifying celecoxib and template compounds as novel inhibitors of signal transducer and activator of transcription 3 (STAT3).

  2011cited by this paper
• Identification of 2-oxatriazines as highly potent pan-PI3K/mTOR dual inhibitors.

  2011cited by this paper
• Low-dose drug combinations along molecular pathways could maximize therapeutic effectiveness while minimizing collateral adverse effects.

  2011cited by this paper
• Open Innovation for Phenotypic Drug Discovery: The PD2 Assay Panel

  2011cited by this paper
• Drugging the PI3 kinome: from chemical tools to drugs in the clinic.

  2010cited by this paper
• Phenotypic screening: Fishing for neuroactive compounds.

  2010cited by this paper
• Discovery of (thienopyrimidin-2-yl)aminopyrimidines as potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitors for the treatment of cancer.

  2010cited by this paper
• Single agents with designed combination chemotherapy potential: synthesis and evaluation of substituted pyrimido[4,5-b]indoles as receptor tyrosine kinase and thymidylate synthase inhibitors and as antitumor agents.

  2010cited by this paper
• Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).

  2010cited by this paper
• 6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.

  2010cited by this paper
• Oxa‐azaspiro Derivatives: a Novel Class of Triple Re‐uptake Inhibitors

  2010cited by this paper
• Hybrid inhibitors of phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR): design, synthesis, and superior antitumor activity of novel wortmannin-rapamycin conjugates.

  2010cited by this paper
• Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor.

  2010cited by this paper
• PKI-179: an orally efficacious dual phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor.

  2010cited by this paper
• 1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.

  2010cited by this paper
• Discovery of 1-(3-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}phenyl)-2-imidazolidinone (GSK163090), a Potent, selective, and orally active 5-HT1A/B/D receptor antagonist.

  2010cited by this paper
• 2,4-Diamino-5-methyl-6-substituted arylthio-furo[2,3-d]pyrimidines as novel classical and nonclassical antifolates as potential dual thymidylate synthase and dihydrofolate reductase inhibitors.

  2010cited by this paper
• Lead optimization of N-3-substituted 7-morpholinotriazolopyrimidines as dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors: discovery of PKI-402.

  2010cited by this paper
• Identification of GNE-477, a potent and efficacious dual PI3K/mTOR inhibitor.

  2010cited by this paper
• Design, synthesis, and X-ray crystal structure of classical and nonclassical 2-amino-4-oxo-5-substituted-6-ethylthieno[2,3-d]pyrimidines as dual thymidylate synthase and dihydrofolate reductase inhibitors and as potential antitumor agents.

  2009cited by this paper
• Design, synthesis, and X-ray crystal structures of 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors.

  2009cited by this paper
• The protein tyrosine kinase inhibitors imatinib and nilotinib strongly inhibit several mammalian alpha-carbonic anhydrase isoforms.

  2009cited by this paper
• Structure of Protein Interaction Networks and Their Implications on Drug Design

  2009cited by this paper
• Molecular docking and ligand specificity in fragment-based inhibitor discovery.

  2009cited by this paper
• Targeting the phosphoinositide 3-kinase pathway in cancer

  2009cited by this paper
• Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc.

  2009cited by this paper
• Rapid behavior—based identification of neuroactive small molecules in the zebrafish

  2009cited by this paper
• ATP-competitive inhibitors of the mammalian target of rapamycin: design and synthesis of highly potent and selective pyrazolopyrimidines.

  2009cited by this paper
• Synthesis, binding affinity and SAR of new benzolactam derivatives as dopamine D3 receptor ligands.

  2009cited by this paper
• Design, synthesis and biological evaluation of novel dual inhibitors of acetylcholinesterase and beta-secretase.

  2009cited by this paper
• Discovery of potent and selective inhibitors of the mammalian target of rapamycin (mTOR) kinase.

  2009cited by this paper
• Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent

  2009cited by this paper
• Discovery of ABT-263, a Bcl-family protein inhibitor: observations on targeting a large protein–protein interaction

  2008cited by this paper
• Targeted polypharmacology: Discovery of dual inhibitors of tyrosine and phosphoinositide kinases

  2008cited by this paper
• Potent dual thymidylate synthase and dihydrofolate reductase inhibitors: classical and nonclassical 2-amino-4-oxo-5-arylthio-substituted-6-methylthieno[2,3-d]pyrimidine antifolates.

  2008cited by this paper
• 6-[2-(4-Aryl-1-piperazinyl)ethyl]-2H-1,4-benzoxazin-3(4H)-ones: dual-acting 5-HT1 receptor antagonists and serotonin reuptake inhibitors.

  2008cited by this paper
• Discovery of potent, orally bioavailable, selective 5-HT1A/B/D receptor antagonists.

  2008cited by this paper
• Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

  2008cited by this paper
• Design, synthesis, and biological evaluation of classical and nonclassical 2-amino-4-oxo-5-substituted-6-methylpyrrolo[3,2-d]pyrimidines as dual thymidylate synthase and dihydrofolate reductase inhibitors.

  2008cited by this paper
• Discovery of multitarget inhibitors by combining molecular docking with common pharmacophore matching.

  2008cited by this paper
• The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .

  2008cited by this paper
• Novel 5-HT(1A/1B/1D) receptors antagonists with potent 5-HT reuptake inhibitory activity.

  2008cited by this paper

• Pushing the Ligand Efficiency Metrics: Relative Group Contribution (RGC) Model as a Helpful Strategy to Promote a Fragment “Rescue” Effect

  2019cites this paper
• New Multitarget Approaches in the War Against Glioblastoma: A Mini-Perspective

  2018cites this paper
• An investigation on 4-thiazolidinone derivatives as dual inhibitors of aldose reductase and protein tyrosine phosphatase 1B, in the search for potential agents for the treatment of type 2 diabetes mellitus and its complications.

  2018cites this paper